Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus

US9795665B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Eric Bergeron · Montréal, CA
• Scott Dusan Pegan · Oak Park, US
• Stuart T. Nichol · Atlanta, US
• Michelle Kay Deaton · Denver, US

Key dates

• Filing date: Aug 13, 2013
• Grant date: Oct 24, 2017
• Expiry date: Sep 8, 2033

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.